Inhibition of the RXRA-PPARα-FABP4 signaling pathway alleviates vascular cellular aging by an SGLT2 inhibitor in an atherosclerotic mice model.

Weiwei Zhang, Linghuan Wang, Yujia Wang, Yan Fang, Ruihua Cao, Zhiyi Fang, Dong Han, Xu Huang, Zhenghui Gu, Yingjie Zhang, Yan Zhu, Yan Ma, Feng Cao

Department of Cardiology, The Second Medical Centre, Chinese PLA General Hospital, National Clinical Research Center for Geriatric Diseases, Beijing, 100853, China.Department of Cardiology, The Second Medical Centre, Chinese PLA General Hospital, National Clinical Research Center for Geriatric Diseases, Beijing, 100853, China. · pubmed

Paper

Abstract

Atherosclerosis is the pathological cause of atherosclerotic cardiovascular disease (ASCVD), which rapidly progresses during the cellular senescence. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce major cardiovascular events in patients with ASCVD and have potential antisenescence effects. Here, we investigate the effects of the SGLT2 inhibitor dapagliflozin on cellular senescence in atherosclerotic mice. Compared with ApoE

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper investigates the effects of an SGLT2 inhibitor on cellular senescence in atherosclerotic mice, which is relevant to the understanding of aging mechanisms and potential interventions to alleviate age-related vascular issues. However, the study appears to focus on a specific treatment rather than addressing the root causes of aging, limiting its overall impact on the field of longevity research.

Author of this paper? Send a correction.